Medindia

X

GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimer's Disease Candidate Vaccines

Friday, October 24, 2008 General News J E 4
Advertisement
VIENNA, Austria, October 23 GlaxoSmithKline BiologicalsS.A. (GSK) and AFFiRiS GmbH announced today the execution of a collaborationagreement granting GSK exclusive rights to AFFiRiS's Alzheimer's diseasevaccine programmes, aimed at treating Alzheimer's by targeting beta-amyloid.

As part of the agreement GSK is acquiring exclusive rights to develop andcommercialise two Alzheimer's disease vaccine candidates that are based onAFFiRiS AFFiTOPE technology and are currently in Phase I clinicaldevelopment. AFFiRiS is also granting GSK an exclusive option to develop andcommercialise alternative Alzheimer's disease vaccine candidates which are inpreclinical development.

Under the terms of the agreement, AFFiRiS will receive an up-frontpayment of EUR 22.5 million (GBP17.5 million) and could be eligible forfuture milestone payments and royalties. The total potential value of theagreement could reach EUR 430 million (GBP334 million) in the event of fullcommercial success of the candidate vaccines. This agreement is subject togovernmental authority approval.

Central to the deal is the AFFiRiS AFFiTOPE technology which allows thedesign of proteins with very specific binding characteristics that areideally suited for the development of vaccines against disease-causing"rogue" human proteins such as beta-amyloid which is central to the pathologyof Alzheimer's disease.

Commenting on the agreement, Walter Schmidt, co-founder and CEO ofAFFiRiS, stated: "We are pleased that we could secure GSK Biologicals, one ofthe world's leading vaccine companies, in collaborating on the developmentour Alzheimer's disease vaccine programs. This deal brings together twocompanies with strong innovation, vaccine development and commercialisationcapabilities and experience."

Jean Stephenne, President and General Manager of GlaxoSmithKlineBiologicals, said "We are impressed with the AFFiRiS technology - combinedwith our expertise in innovative adjuvant systems this collaboration willimprove our chance of success in the discovery of new treatments against thismajor disease."

Frank Mattner, co-founder and CSO of AFFiRiS, added: "For the treatmentof chronic diseases, our AFFiTOPE technology has the potential to deliverinnovative vaccines capable of inducing immune responses, with thepossibility of beneficial therapeutic effects. We hope that this agreementwill ultimately deliver a therapeutic benefit to Alzheimer's patients."

Notes to Editors

About GSK GlaxoSmithKline - one of the world's leading research-basedpharmaceutical and healthcare companies - is committed to improving thequality of human life by enabling people to do more, feel better and livelonger. For company information, visit http://www.gsk.com.

About GlaxoSmithKline Biologicals GlaxoSmithKline Biologicals (GSKBiologicals) is a global vaccine company which has shown to be a leader ininnovation. The company is active in the fields of vaccine research,development and production with over 30 vaccines approved for marketing and20 more in development. Headquartered in Belgium, GSK Biologicals has 14manufacturing sites strategically positioned around the globe. In 2007 GSKBiologicals distributed 1.1 billion doses of vaccines to 169 countries inboth developed and the developing world - an average of 3 million doses aday. GSK Biologicals employs over 9,000 people worldwide including more than1,600 passionate scientists engaged in research aimed at discoveringinnovative vaccines that contribute to the health and well-being of people ofall generations around the world.

About AFFiRiS AFFiRiS GmbH develops peptide-based vaccines for thetreatment of Alzheimer's disease, atherosclerosis and other diseases thaturgently require a medical solution. The company has established platformtechnologies and has a worldwide patent portfolio covering their vaccinecandidates. The company employs 35 highly qualified members of staff on600msquared of rented laboratory facilities at the Campus Vienna Biocenter(http://www.affiris.com).GlaxoSmithKline Enquiries: UK Media enquiries: Philip Thomson, +44(0)20-8047-5502; Claire Brough, +44(0)20-8047-5502; Alice Hunt, +44(0)20-8047-5502; Gwenan White, +44(0)20-8047-5502 US Media enquiries: Nancy Pekarek, +1-919-483-2839; Mary Anne Rhyne, +1-919-483-2839; Sarah Alspach, +1-215-751-7709 European Analyst/Investor enquiries: David Mawdsley, +44(0)20-8047-5564; Sally Ferguson, +44(0)20-8047-5543; Gary Davies, +44(0)20-8047-5503 US Analyst/ Investor enquiries: Tom Curry, +1-215-751-5419 AFFiRiS GmbH Enquiries: Campus Vienna Biocenter 2, 1030 Vienna, Austria Dr. Walter Schmidt +43-1-798-1575-10 Distribution: PR&D - Public Relations for Research & Education Campus Vienna Biocenter 2 1030 Vienna Austria, T +43-1-505-70-44, E contact@prd.at, W: http://www.prd.at

SOURCE AFFiRiS GmbH, GlaxoSmithKline Biologicals (GSK Biologicals)
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Addrenex Pharmaceuticals Initiates Phase 2 Trial o...
S
Plexus Systems, Inc. to Exhibit at Metalform Mexic...